Surgery Websites
Transplant Surgery »  Meet the Team »  Pediatric Hepatology »  Philip Rosenthal, M.D.
Philip Rosenthal, M.D.

Philip Rosenthal, M.D.

Professor of Pediatrics and Surgery
Director of Pediatric Hepatology Research
Director, Pediatric Hepatology

Contact Information

Academic Office
Room MU 415, Box 0136
University of California, San Francisco
San Francisco, CA 94143-0136
(415) 476-5892
(415) 476-1343 Fax
Open Popup

1967-71 State Univ. of N.Y. at Albany, Albany, NY, B.S. Magna Cum Laude, Biology
1971-75 State Univ. of N.Y. Downstate Med. Ctr. Brooklyn, NY, M.D. Magna Cum Laude

  • 1975-76 Albert Einstein/Bronx Mun. Hosp., NY, Intern Pediatrics
  • 1976-78 Albert Einstein/Bronx Mun. Hosp., NY, Resident Pediatrics
  • 1978-81 University of California, San Francisco, Fellow Pediatric Gastroenterology
  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Subspeciality in Pediatric Gastroenterology
  • American Board of Pediatrics, Certificate of Added Qualification in Transplant Hepatology
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Liver Center
  • Pediatric Liver Transplant Program
  • Pediatric Intestinal Rehabilitation and Transplantation Program
  • Bioartificial liver devices
  • Genetics and immunology of biliary atresia
  • Idiopathic neonatal hepatitis
  • Pediatric Acute Liver Failure (PALF)
  • Quality of life after liver transplants

Philip Rosenthal, M.D. is Professor of Pediatrics and Surgery, Medical Director of the Pediatric Liver Transplant Program. and Director of Pediatric Hepatology at UCSF.  Rosenthal completed his medical training at Downstate Medical Center and the Albert Einstein Medical Center in New York. He then completed a fellowship in pediatric gastroenterology at UCSF. He joined the UCSF faculty in 1995 after serving as Professor of Pediatrics at University of California, Los Angeles (UCLA). 

A  pediatric hepatologist at the UCSF Benioff Children's Hospital, Rosenthal is internationally renowned for the care of children with liver disease, including liver cancer, and  those undergoing liver transplantation. In addition, Rosenthal has and currently serves as Principal Investigator on numerous clinical trials to improve the care of patients with pediatric liver disease.

Rosenthal has won numerous honors for his research including work on the pharmaceutical treatment of hepatitis B and C, genetics and immunology of biliary atresia and the quality of life after liver transplants in children. He is a consultant to organizations such as the American Liver Foundation, Parents of Kids with Infectious Diseases, Alagille Syndrome Alliance, Studies of Pediatric Liver Transplantation (SPLIT), Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). He is also on editorial boards and a regular reviewer for leading professional journals.

  Confired By    
  • Murray Davidson Award
  • American Academy of Pediatrics
  • 2013
  • Chancellor's Award for Public Service
  • UCSF
  • 2002
  • Rosenthal is pursuing research on the pharmaceutical treatment of hepatitis B and C, genetics and immunology of biliary disease, use of bioartificial liver support utilizing porcine hepatocytes for patients with fulminant liver failure, as well as researching the quality of life following liver transplantation in children. 

    Clinical Research

    Rosenthal is principal investigator on numerous clinical trials including the following:

    View all trials 

    Data provided by UCSF Profiles, powered by CTSI
    • Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda
      Sponsor ID:
      Funding Period:
      Apr 2020
      Mar 2025
      Co-Principal Investigator
    • Childhood Liver Disease Research Network (ChiLDReN) - UCSF (CC)
      Sponsor ID:
      Funding Period:
      Sep 2002
      May 2024
      Principal Investigator
    • Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline
      Sponsor ID:
      Funding Period:
      Jun 2018
      May 2023
      Principal Investigator
    Data provided by UCSF Profiles, powered by CTSI
    1. Hughes E, Wallender E, Kajubi R, Jagannathan P, Ochieng T, Kakuru A, Kamya MR, Clark TD, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM. Piperaquine induced QTc prolongation decreases with repeated monthly dihydroartemisinin-piperaquine dosing in pregnant Ugandan women. Clin Infect Dis. 2021 Dec 02. View in PubMed
    2. Taylor SA, Venkat V, Arnon R, Gopalareddy VV, Rosenthal P, Anderson SG, Anand R, Daniel JF, Society of Pediatric Liver Transplantation. Organ-specific comorbidities are associated with distinct complications after liver transplantation for biliary atresia. Liver Transpl. 2021 Nov 25. View in PubMed
    3. Wallender E, Ali AM, Hughes E, Kakuru A, Jagannathan P, Muhindo MK, Opira B, Whalen M, Huang L, Duvalsaint M, Legac J, Kamya MR, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Nat Commun. 2021 Nov 18; 12(1):6714. View in PubMed
    4. Leung DH, Sorensen LG, Ye W, Hawthorne K, Ng VL, Loomes KM, Fredericks EM, Alonso EM, Heubi JE, Horslen SP, Karpen SJ, Molleston JP, Rosenthal P, Sokol RJ, Squires RH, Wang KS, Kamath BM, Magee JC, Childhood Liver Disease Research Network (ChiLDReN). Neurodevelopmental Outcomes in Children with Inherited Liver Disease and Native Liver. J Pediatr Gastroenterol Nutr. 2021 Oct 22. View in PubMed
    5. Kreutzfeld O, Tumwebaze PK, Byaruhanga O, Katairo T, Okitwi M, Orena S, Rasmussen SA, Legac J, Conrad MD, Nsobya SL, Aydemir O, Bailey JA, Duffey M, Cooper RA, Rosenthal PJ. Decreased susceptibility to dihydrofolate reductase inhibitors associated with genetic polymorphisms in Ugandan Plasmodium falciparum isolates. J Infect Dis. 2021 Aug 30. View in PubMed
    6. View All Publications


    Site Directory